- Home
- KSCP vs SCYX Comparison
KSCP vs SCYX Comparison
Compare KSCP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSCP
- SCYX
- Stock Information
- Founded
- KSCP 2013
- SCYX 1999
- Country
- KSCP United States
- SCYX United States
- Employees
- KSCP N/A
- SCYX N/A
- Industry
- KSCP Telecommunications Equipment
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- KSCP Telecommunications
- SCYX Health Care
- Exchange
- KSCP Nasdaq
- SCYX Nasdaq
- Market Cap
- KSCP N/A
- SCYX 40.9M
- IPO Year
- KSCP 2022
- SCYX 2014
- Fundamental
- Price
- KSCP $2.82
- SCYX $0.98
- Analyst Decision
- KSCP Strong Buy
- SCYX Buy
- Analyst Count
- KSCP 1
- SCYX 1
- Target Price
- KSCP $16.00
- SCYX N/A
- AVG Volume (30 Days)
- KSCP 262.9K
- SCYX 129.0K
- Earning Date
- KSCP 05-15-2025
- SCYX 03-12-2025
- Dividend Yield
- KSCP N/A
- SCYX N/A
- EPS Growth
- KSCP N/A
- SCYX N/A
- EPS
- KSCP N/A
- SCYX N/A
- Revenue
- KSCP $11,005,000.00
- SCYX $3,746,000.00
- Revenue This Year
- KSCP N/A
- SCYX $1,541.00
- Revenue Next Year
- KSCP $19.53
- SCYX $111.43
- P/E Ratio
- KSCP N/A
- SCYX N/A
- Revenue Growth
- KSCP N/A
- SCYX N/A
- 52 Week Low
- KSCP $2.52
- SCYX $0.82
- 52 Week High
- KSCP $31.50
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- KSCP 19.17
- SCYX 43.38
- Support Level
- KSCP $3.78
- SCYX $1.00
- Resistance Level
- KSCP $4.25
- SCYX $1.06
- Average True Range (ATR)
- KSCP 0.41
- SCYX 0.07
- MACD
- KSCP 0.05
- SCYX 0.00
- Stochastic Oscillator
- KSCP 11.19
- SCYX 41.99
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.